ZEVASKYN's commercial ramp in ultra-rare RDEB determines whether Abeona can build a self-sustaining rare disease franchise before cash erodes

Abeona Therapeutics is a commercial-stage biotech company with an FDA-approved cell therapy for wounds in recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering disease, though it faces competition from a simpler topical rival.

ZEVASKYN is an FDA-approved autologous cell therapy for wounds in adult and pediatric RDEB patients, a disease with an estimated U.S. prevalence of roughly 3,000 RDEB patients. The thesis turns on whether ZEVASKYN can achieve a treatment cadence that grows revenue faster than the $17M quarterly cash burn before the $168M cash reserve is consumed. The primary competitive risk is Castle Biosciences-backed Krystal Biotech's Vyjuvek, an approved in-office topical gene therapy for RDEB wounds that offers a far simpler administration profile.